Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-12-01T00:09:36.119Z Has data issue: false hasContentIssue false
  • English
  • Français

Vancomycin-Resistant Enterococci in Canada: Results from the Canadian Nosocomial Infection Surveillance Program, 1999–2005

Published online by Cambridge University Press:  02 January 2015

Marianna Ofner-Agostini ,
B. Lynn Johnston ,
Andrew E. Simor ,
John Embil ,
Anne Matlow ,
Michael Mulvey ,
Debbie Ormiston ,
John Conly  and
Canadian Nosocomial Infection Surveillance Program
Marianna Ofner-Agostini
Affiliation:
Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada, Ottawa, Canada
B. Lynn Johnston*
Affiliation:
Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
Andrew E. Simor
Affiliation:
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
John Embil
Affiliation:
Health Sciences Centre, Winnipeg, Manitoba, Canada
Anne Matlow
Affiliation:
Hospital for Sick Children, Toronto, Ontario, Canada
Michael Mulvey
Affiliation:
National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
John Conly
Affiliation:
Foothills Medical Centre, Calgary, Alberta, Canada
*
Queen Elizabeth II Health Sciences Centre, Room 5014, Dickson Building, 1278 Tower Road, Halifax, NS, B3H 2Y9, Canada ([email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Surveillance for vancomycin-resistant enterococci (VRE) in sentinel Canadian hospitals has been conducted since 1999. From 1999 to 2005, the rate of VRE detection increased from 0.37 to 1.32 cases per 1,000 patients admitted, and the rate of VRE infection increased from 0.02 to 0.05 cases per 1,000 patients admitted. Thirty-three percent of all patients with VRE detected that were reported during 1999-2005 were identified in 2005, with increases seen in all regions of Canada. Although the incidence rate of VRE carriage in Canada is increasing, it remains very low.

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 29 , Issue 3 , March 2008 , pp. 271 - 274
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Chang, S, Sievert, DM, Hageman, JC, et al.Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003;348:1242–1247.CrossRefGoogle ScholarPubMed
2.Ofner-Agostini, ME, Conly, J, Paton, S, et al.Vancomycin-resistant enterococci (VRE) in Canada—results of the Canadian Nosocomial Infection Surveillance Program 1996: VRE point prevalence surveillance project. Can J Infect Dis 1997;8:73–78.Google Scholar
3.National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1990– May 1999, issued June 1999. Am J Infect Control 1999;27:520–532.Google Scholar
4.Garner, JS, Jarvis, WR, Emori, TG, Horan, TC, Hughes, JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128–140.Google Scholar
5.Ofner-Agostini, M, Varia, M, Johnston, L, et al.Infection control and antimicrobial restriction practices for antimicrobial resistant organisms (AROs) in Canadian tertiary care hospitals. Am J Infect Control 2007;35:563–568.Google Scholar
6.Muto, CA, Jernigan, JA, Ostrowsky, BE, et al.SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003;24:362–386.Google Scholar
7.Simor, AE, Ofner-Agostini, M, Gravel, D, et al.; Canadian Hospital Epidemiology Committee; Canadian Nosocomial Infection Surveillance Program, Public Health Agency of Canada. Surveillance for mefhicillin-resistant Staphylococcus aureus in Canadian hospitals—a report update from the Canadian Nosocomial Infection Surveillance Program. Can Commun Dis Rep 2005;31:33–40. Available at: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/05pdf/cdr3103.pdf. Accessed January 28, 2008.Google Scholar
8.Johnston, BL, Conly, JM. Clostridium difficile: the evolving story. Can J Infect Dis Med Microbiol 2007;18:341–345.Google Scholar
9.Johnston, L, Ofner-Agostini, ME, Holton, D, et al.Laboratory and infection control protocols for vancomycin-resistant enterococci (VRE): a survey of CHEC facilities. In: 67th Conjoint Meeting on Infectious Diseases; October 31–November 4, 1999; Edmonton, Alberta, Canada. Abstract P49.Google Scholar